Drug Trial Radar · NCT06971900
GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria
Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Apr 4, 2025
Primary completion
Nov 22, 2025
Study completion Nov 24, 2025
Sponsor
- Lead sponsor
- Portal Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Celerion
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)
Conditions
- Erythropoietic Protoporphyria (EPP)
Interventions
PORT-77Drug
Active oral dose form
PlaceboDrug
Matching inactive oral dose form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma PPIX levelTime frame: 9 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.